Lineage Cell Therapeutics (LCTX) Financials

$1.03

$-0.27 (-20.77%)

As on 09-Sep-2026 15:44EDT

Market cap

$278 Mln

Revenue (TTM)

$13 Mln

P/E Ratio

--

P/B Ratio

4.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	13.08	14.56	9.50	8.95	14.70	3.90
Cost of Revenue	0.45	0.85	0.33	0.67	0.73	1.43
Gross Profit	12.64	13.71	9.17	8.27	13.98	2.47
Operating Expenses	39.49	35.49	30.64	33.01	36.50	51.68
Operating Profit (EBIT)	-26.85	-21.78	-21.48	-24.73	-22.52	-49.21
Other Income	--	--	--	--	-4.12	5.94
Profit before Tax	-37.39	-68.65	-18.58	-23.28	-25.81	-43.27
Provision for Tax	-5.28	-5.11	0.03	-1.80	0.54	-4.71
Profit after Tax (Net Income)	-32.26	-63.53	-18.61	-21.49	-26.27	-43.02
Minority Interest	-0.16	-0.17	-0.03	-0.01	-0.08	-0.25
Consolidated Profit	--	--	--	--	-26.27	-43.02

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	60.92	44.55	78.38	63.42	73.34	92.22
Minority Interest	-0.16	--	--	--	-1.40	-1.32
Non-Current Liabilities	38.41	57.87	22.23	21.04	32.75	36.53
Current Liabilities	8.02	11.37	13.98	17.96	18.98	47.12
Total Liabilities	114.24	112.58	113.22	101.02	123.66	174.55

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	53.25	53.43	62.22	62.58	63.66	63.00
Current Assets	52.97	59.16	51.00	38.44	60.00	111.55
Total Assets	114.24	112.58	113.22	101.02	123.66	174.55
Total Debt*	2.30	2.42	2.51	2.95	3.90	2.80
Net Current Assets	44.95	47.79	37.02	20.48	41.02	64.43

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-18.92	-23.09	-28.57	1.06	-23.56
Cash Flow from Investing Activities	--	-13.46	-2.31	46.45	-46.16	9.75
Cash from Financing Activities	--	26.95	35.86	6.42	1.63	36.93
Net Cash Inflow / Outflow	--	--	--	--	-43.47	23.11

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.14	-0.28	-0.09	-0.12	-0.15	-0.26
Cash EPS ($)	--	-0.27	-0.09	-0.12	-0.15	-0.25
Adjusted Book Value ($)	--	0.19	0.39	0.37	0.43	0.55
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.08	-0.12	-0.17	0.01	-0.14
Free Cash Flow per Share ($)	--	-0.08	-0.12	-0.17	0.00	-0.14

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-99.38	-25.27	-29.92	-30.50	-44.11
ROE (%)	-61.47	-103.36	-26.25	-31.42	-31.74	-45.66
ROA (%)	-29.90	-56.27	-17.37	-19.13	-17.62	-30.46
EBIT Margin (%)	-285.75	-471.61	-195.62	-260.28	-175.56	-1,110.63
Net Margin (%)	-246.58	-436.47	-195.90	-240.20	-248.28	-437.41
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	19.87	0.53	0.06	-0.39	2.77	4.04
EBIT Growth (%)	-143.80	-269.43	20.19	9.80	40.35	-63.61
Net Profit Growth (%)	21.06	-241.41	13.39	18.22	38.93	-108.33
EPS Growth (%)	24.41	-1.97	0.25	0.19	0.40	-0.86
Book Value Growth (%)	9.95	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-6.05	-5.41	-8.76	-7.57	-9.55
Price / Book Value	4.48	8.63	1.28	2.97	2.71	4.45
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-8.84	-4.87	-3.08	-6.89	-5.78	-8.38
Close Price ($)	--	1.67	0.50	1.09	1.17	2.45
High Price ($)	--	2.09	1.61	1.58	2.58	3.13
Low Price ($)	--	0.37	0.48	0.90	1.02	1.55
Market Cap ($ Cr)	278.20	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.05	0.03	0.05	0.05	0.03
Short term debt to equity ratio	0.02	0.02	0.01	0.01	0.01	0.01
Current Ratio	6.61	5.20	3.65	2.14	3.16	2.37
Quick Ratio	6.61	--	--	--	3.16	--
Interest Coverage	--	--	--	--	-4.98	-21,635.00

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	6.04	10.73	6.72	8.33	2.02	1,312.63
Asset Turnover	0.12	0.13	0.09	0.08	0.10	0.03
Receivable days	--	27.60	26.59	21.27	638.90	2,397.38
Inventory Days	--	--	--	0.00	0.00	--
Payable days	--	759.68	1,762.82	1,209.24	1,489.10	788.13
Cash Conversion Cycle	--	--	--	-1,187.97	-850.20	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.